Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners updates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL). During the second quarter of fiscal year 2025, Incannex ...

Incannex secured a strategic financing agreement with Arena Investors, which includes a $50M ELOC with Arena Business Solutions. IHL-42X had positive top-line results from a pharmacokinetics (PK) and ...

Positive IHL-42X PK findings for the treatment of Obstructive Sleep Apnea (OSA) support future 505(b)(2) New Drug Application (NDA) submissionNew ...

Detailed price information for Artelo Biosciences Inc (ARTL-Q) from The Globe and Mail including charting and trades.

Rezolute (RZLT) announced that the independent data monitoring committee reviewed safety and pharmacokinetics in eight infant patients in the ...

Recently published study focused on the evaluation of a novel etomidate analogue, methoxyethyl etomidate hydrochloride (ET-26), in healthy volunteers to assess its safety, tolerability, ...

"We are extremely pleased that the FDA granted Fast Track Designation to CUSP06," said Eric Slosberg, PhD, Chief Development Officer of OnCusp Therapeutics. "The early results from our Phase 1 trial ...

Adial Pharmaceuticals received a U.S. patent for genetic marker-based treatment methods and completed a pharmacokinetics ...

The inhaled monoclonal antibody IN-006 shows promise in COVID-19 treatment, with high airway antibody levels and a favorable safety profile in healthy adults.

Silo Pharma (NASDAQ: SILO) announced encouraging early results from its ongoing study evaluating the pharmacokinetics, safety and tolerability of it ...

Aims Clopidogrel is the most commonly prescribed thienopyridine as part of dual anti-platelet therapy for the treatment of ...

Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, ...